Dermira, Inc. (NASDAQ:DERM) – Investment analysts at Leerink Swann dropped their Q3 2017 earnings per share estimates for Dermira in a report released on Monday. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will post earnings of ($1.03) per share for the quarter, down from their previous forecast of ($1.00). Leerink Swann also issued estimates for Dermira’s Q4 2017 earnings at ($1.29) EPS, FY2017 earnings at ($4.06) EPS, FY2018 earnings at ($2.24) EPS and FY2019 earnings at $0.38 EPS.
Several other research analysts also recently weighed in on the stock. BidaskClub downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Evercore ISI began coverage on shares of Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price objective on the stock. Five investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $43.80.
WARNING: “Leerink Swann Comments on Dermira, Inc.’s Q3 2017 Earnings (DERM)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2796485/leerink-swann-comments-on-dermira-inc-s-q3-2017-earnings-derm.html.
Shares of Dermira (DERM) opened at 22.56 on Thursday. The firm has a 50-day moving average of $28.50 and a 200 day moving average of $30.77. The firm’s market capitalization is $936.71 million. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75.
Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.04. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The business had revenue of $1.07 million during the quarter, compared to analyst estimates of $1 million.
In other news, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Christopher M. Griffith sold 1,312 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $27.07, for a total transaction of $35,515.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,812 shares of company stock worth $482,231. Corporate insiders own 13.30% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in shares of Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares in the last quarter. KCG Holdings Inc. purchased a new stake in shares of Dermira during the first quarter valued at approximately $215,000. Legal & General Group Plc increased its stake in shares of Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares in the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Dermira during the first quarter valued at approximately $256,000. Institutional investors own 84.57% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.